The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.
about
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatristsThe Role of Dopamine and Its Dysfunction as a Consequence of Oxidative StressAsenapine for bipolar disorderThe influence of atypical antipsychotic drugs on sexual functionThe risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysisCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewChlorpromazine-Induced Hyperprolactinemia on Rat's UterusAdjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study.Pseudocyesis, delusional pregnancy, and psychosis: The birth of a delusion.Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers.Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.Prolactin related symptoms during risperidone maintenance treatment: results from a prospective, multicenter study of schizophrenia.Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania.Does environmental confounding mask pleiotropic effects of a multiple sclerosis susceptibility variant on vitamin D in psychosis?Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs.Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional DisorderPharmacological characterization of a novel potent, selective, and orally active phosphodiesterase 10A inhibitor, PDM-042 [(E)-4-(2-(2-(5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)vinyl)-6-(pyrrolidin-1-yl)pyrimidin-4-yl)morpholine] in rats: potReduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.Emerging drugs for schizophrenia: an update.Potential use of lurasidone for the treatment of bipolar psychosis.The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials.Antipsychotic Medication Use Among Publicly Insured Pregnant Women in the United States.Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.Phosphodiesterase 10 inhibitors in clinical development for CNS disorders.Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch.Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia.Lack of tolerable treatment options for patients with schizophrenia.Toxicity assessment of molindone hydrochloride, a dopamine D2/D5 receptor antagonist in juvenile and adult rats.Modeling of prolactin response following dopamine D2 receptor antagonists in rats: can it be translated to clinical dosing?Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications.Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study.Effects of 2-bromoterguride, a dopamine D2 receptor partial agonist, on cognitive dysfunction and social aversion in rats.Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia.Calcium and Vitamin D Supplementation in Boys with Risperidone-Induced Hyperprolactinemia: A Randomized, Placebo-Controlled Pilot Study.Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence.
P2860
Q26747123-CC066B71-495D-43A5-8F5F-16FA9886CE74Q26771824-69F3DE5E-B9B8-4A39-B5A7-72E72659FD7EQ26775399-6D766927-1C0B-4A0B-90AE-C8FA68F278DFQ26799708-33F6CD57-C41C-4920-9D26-3A3B0E9DE165Q26996493-B152F380-36CA-43B0-A67F-441D23C2B72EQ28079821-0CAF174C-2B0E-4D29-B9F1-4F02A936F8A8Q28607320-8B60C1F6-A0C0-49AA-AED6-0E72CA85308BQ30490025-FD59B4D4-64E1-49B1-B510-72C4C0D90158Q33879147-C28DF466-D782-43DA-A6B1-27A65B82C44AQ34047598-8D35AB70-77F2-4DCB-81C4-8C6D7B2D0F4BQ35142660-4186403A-56FD-4513-AFAB-C750263CC49DQ35754726-C09A5211-12B3-433C-993D-8CC547AEDEA8Q35816572-F2248375-7648-44A6-A075-A2D4A9E90C2DQ36188000-293E3058-9E61-4E84-9E58-9F2398FF4610Q36294140-5E6FACAD-386C-4556-AB6B-635858F08196Q36848315-14B6FD21-2E4F-4BB8-A1C7-A08D3AB77DEEQ36972523-CAAC0EC4-C1A7-408D-B923-D1E52E1240EAQ36997248-134651D0-2B8D-44F8-AE4A-3C33B7084915Q37591807-87D952D2-2163-477C-9595-2457C84EF920Q37735342-3648A238-9737-4A4F-BBE2-AD0EB971F00EQ38252404-0DC056E6-CCCE-403C-BBC8-8A8F2F9BC875Q38336677-10673C76-E1DC-4CE3-9ABC-8F63A8B35C17Q38592139-0B1B3313-6347-4CB3-9757-3E0AAD96535BQ38636378-FCE9BACF-1D54-4071-9EEA-9142D11A9A13Q38724641-17EE1939-2E62-4D82-B73A-9C900C8FECF0Q38778145-5363584C-3D4F-4FC1-B8E5-176FFF69E399Q38989642-E897041D-98F2-4B64-B539-CAEDA2670FA3Q39029199-19A79163-BD2F-4EC1-A967-395BB6ED390BQ39162868-838B17FE-FBE9-4642-9DFC-7481DDE6223EQ40571585-8DF38C90-CBF4-4276-80FE-23379374C845Q42120078-41CFE2BD-66E7-4439-8BCC-6BA60FB3FF08Q46425205-F95F27FE-0E14-49BD-956C-CDA363675EDDQ47126919-86398527-FD2D-4BB8-AE33-BA81522DAB9FQ47555827-6AF70B72-92A8-4A89-81E4-F0E3AC545E74Q47556007-96BFF984-C2AE-4AD6-AA52-DF2C9143E174Q47669147-7085456A-C962-4D5D-8F48-A2E56B464F81Q47814439-E7C791EF-ADB5-48C2-B02B-4E8746BC32A9Q47854037-DA2D82BD-2344-48AF-878E-4E483FB13382Q49598291-6D28769F-3B31-43C2-9025-7A8466ACA735Q50103957-E2A3BDAE-028E-4BB7-810E-403CCB77ACCB
P2860
The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The effects of novel and newly ...... evels: a comprehensive review.
@ast
The effects of novel and newly ...... evels: a comprehensive review.
@en
type
label
The effects of novel and newly ...... evels: a comprehensive review.
@ast
The effects of novel and newly ...... evels: a comprehensive review.
@en
prefLabel
The effects of novel and newly ...... evels: a comprehensive review.
@ast
The effects of novel and newly ...... evels: a comprehensive review.
@en
P2093
P2860
P1433
P1476
The effects of novel and newly ...... levels: a comprehensive review
@en
P2093
P2860
P2888
P304
P356
10.1007/S40263-014-0157-3
P50
P577
2014-05-01T00:00:00Z